 |
Phase 3
Stimuvax® is an innovative cancer vaccine designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. MUC1 is over expressed on many cancers such as lung cancer, breast cancer, prostate cancer and colorectal cancer. Stimuvax® is thought to work by stimulating the body's immune system to identify and destroy cancer cells expressing MUC1.
Oncothyreon is developing Stimuvax® in collaboration with Merck KGaA of Darmstadt, Germany (Merck). Merck is conducting a Phase 3 trial of Stimuvax® in patients with unresectable stage III non-small cell lung cancer (NSCLC). This trial, START (Stimulating Targeted Antigenic Responses To NSCLC), is a multi-center, randomized, double-blind, placebo-controlled study that will evaluate patients with documented unresectable stage IIIA or IIIB NSCLC who have had a response or stable disease after at least two cycles of platinum-based chemo-radiotherapy. The study is expected to involve more than 1,300 patients in approximately 30 countries.
For more information on the START study, or to find a participating center and eligibility criteria, go to www.nsclcstudy.com or call 1-800-507-5284. The study is also listed on www.clinicaltrials.gov. If you are located outside North America, START / Stimuvax inquiries can be directed to the Merck Communication Center by telephone at +49 6151 72 5200, via the contact form on www.merck.de or via email at service@merck.de.
|
|
